Rockefeller Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $66.8M | Buy |
149,655
+14,423
| +11% | +$6.73M | 0.12% | 167 |
|
|
2025
Q4 | $61.3M | Buy |
135,232
+42,418
| +46% | +$18.3M | 0.11% | 174 |
|
|
2025
Q3 | $36.3M | Sell |
92,814
-6,924
| -7% | -$2.89M | 0.07% | 253 |
|
|
2025
Q2 | $44.4M | Buy |
99,738
+8,774
| +10% | +$4.04M | 0.1% | 203 |
|
|
2025
Q1 | $44.1M | Sell |
90,964
-7,825
| -8% | -$3.65M | 0.11% | 186 |
|
|
2024
Q4 | $39.8M | Buy |
98,789
+28,240
| +40% | +$13.1M | 0.1% | 195 |
|
|
2024
Q3 | $32.8M | Sell |
70,549
-612
| -0.9% | -$294K | 0.09% | 230 |
|
|
2024
Q2 | $33.4M | Buy |
71,161
+1,280
| +2% | +$556K | 0.09% | 202 |
|
|
2024
Q1 | $29.2M | Buy |
69,881
+9,356
| +15% | +$3.96M | 0.09% | 237 |
|
|
2023
Q4 | $24.6M | Buy |
60,525
+7,635
| +14% | +$2.82M | 0.08% | 249 |
|
|
2023
Q3 | $18.4M | Buy |
52,890
+1,467
| +3% | +$513K | 0.07% | 278 |
|
|
2023
Q2 | $18.1M | Buy |
51,423
+5,695
| +12% | +$1.92M | 0.07% | 292 |
|
|
2023
Q1 | $14.4M | Sell |
45,728
-1,816
| -4% | -$545K | 0.06% | 337 |
|
|
2022
Q4 | $13.7M | Sell |
47,544
-241
| -0.5% | -$73.5K | 0.07% | 301 |
|
|
2022
Q3 | $13.8M | Buy |
47,785
+4,818
| +11% | +$1.39M | 0.07% | 284 |
|
|
2022
Q2 | $12.1M | Buy |
42,967
+6,039
| +16% | +$1.62M | 0.06% | 301 |
|
|
2022
Q1 | $9.64M | Buy |
36,928
+6,807
| +23% | +$1.62M | 0.05% | 380 |
|
|
2021
Q4 | $6.61M | Buy |
30,121
+6,248
| +26% | +$1.21M | 0.03% | 467 |
|
|
2021
Q3 | $4.33M | Buy |
23,873
+6,477
| +37% | +$1.26M | 0.02% | 510 |
|
|
2021
Q2 | $3.51M | Sell |
17,396
-1,346
| -7% | -$282K | 0.02% | 550 |
|
|
2021
Q1 | $4.03M | Buy |
18,742
+7,191
| +62% | +$1.58M | 0.03% | 409 |
|
|
2020
Q4 | $2.73M | Buy |
11,551
+599
| +5% | +$137K | 0.02% | 444 |
|
|
2020
Q3 | $2.98M | Buy |
10,952
+452
| +4% | +$125K | 0.03% | 346 |
|
|
2020
Q2 | $3.05M | Buy |
10,500
+2,282
| +28% | +$619K | 0.03% | 314 |
|
|
2020
Q1 | $1.96M | Buy |
8,218
+5,987
| +268% | +$1.37M | 0.03% | 342 |
|
|
2019
Q4 | $488K | Buy |
2,231
+210
| +10% | +$42.5K | 0.01% | 589 |
|
|
2019
Q3 | $342K | Buy |
2,021
+525
| +35% | +$92.9K | ﹤0.01% | 532 |
|
|
2019
Q2 | $274K | Sell |
1,496
-1,208
| -45% | -$211K | ﹤0.01% | 533 |
|
|
2019
Q1 | $497K | Buy |
2,704
+2,122
| +365% | +$392K | 0.01% | 475 |
|
|
2018
Q4 | $96K | Buy |
582
+532
| +1,064% | +$92.2K | ﹤0.01% | 460 |
|
|
2018
Q3 | $10K | Hold |
50
| – | – | ﹤0.01% | 587 |
|
|
2018
Q2 | $8K | Buy |
+50
| New | +$7.75K | ﹤0.01% | 655 |
|
Other funds holding VRTX
VCM
VPM
Rockefeller Capital Management's VRTX Position: Q1 2026 in Review
Rockefeller Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2026, buying an estimated $6.73M and bringing the position to 149,655 shares worth $66.8M. The position accounts for 0.12% of the portfolio, ranked #167.
Rockefeller Capital Management first reported a position in VRTX in Q2 2018 and has held it in 32 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Rockefeller Capital Management held 149,655 shares of Vertex Pharmaceuticals worth $66.8M as of Q1 2026.
- Rockefeller Capital Management bought 14,423 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.73M.
- Vertex Pharmaceuticals made up 0.12% of Rockefeller Capital Management's portfolio in Q1 2026, its #167 holding.
- Rockefeller Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.